American-Israeli drugmaker with dual HQs in Israel and the U.S.
The Royal College of Nursing and the Royal College of Pharmacy have dropped Teva UK from sponsorships and exhibitions, citing ongoing due diligence and concerns over Teva’s activities. Campaign groups have urged further action across other royal colleges and NHS purchasing decisions. Teva has faced multiple fines for price-fixing and sanctions in recent years.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.